This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Monsanto Investors Should Be Patient for the Harvest

Stocks in this article: MON DD SYT

NEW YORK ( TheStreet) -- With shares of Monsanto (MON - Get Report) back up near a 52-week high, it certainly looks as if the Street's on-again off-again romance with the agriculture giant is back on again. But how long will it last this time? This company is never far from controversy.

When Monsanto is not being vilified for what many believe to be unfair pricing tactics, the company is being attacked for its genetically modified seeds, which have raised health concerns among consumers. This is even though the Food and Drug Administration and other agricultural bodies have certified these seeds as being healthy to eat.

Nevertheless, these issues have not swayed investors from appreciating that Monsanto remains a solid play on the anticipated rise in global food demand. But these shares, which have been up by close to 13% over the past three months, are far from cheap. And with the first-quarter report due out Wednesday, investors will be looking for confirmation that they've planted their faith in the right company.

The Street will be looking for 64 cents in earnings per share on revenue of $3.08 billion, which would represent year-over-year revenue growth of 4.7%. This is while profits are expected to grow year over year by a mere 3%. Will this be enough to drive this stock higher, given that shares are already expensive relative to rivals DuPont (DD) and Syngenta (SYT)?

Let's not forget, not only did Monsanto report a worse-than-expected loss for its fiscal fourth quarter in October, but management also issued weaker-than-expected guidance for this current quarter. So investors should ease into Wednesday's report with some understanding that the numbers are not expected to particularly robust. But Monsanto has always been about more than the numbers.

For instance, even with its 1.5% decline in overall revenue back in October, the company still managed to doubled revenue for cotton seeds to more than to $65 million. Meanwhile the agriculture business posted another strong double-digit gain, jumping close to 14% year over year. This was during what is typically a seasonally weak period for the company.

On Wednesday investors should pay special attention to the details management shares regarding the company's segmental performances. More specifically, can Monsanto accelerate growth in areas like corn, while at the same time fixing weak areas like soybeans?

I believe the federal government's plan to eliminate restrictions on corn and soybean seeds that are genetically engineered to resist a common weed killer will help not only farmers, but companies like Monsanto. There were concerns that the herbicide known as 2,4-D will eventually becomes toxic to the plants early in their growth.

However, the U.S. Department of Agriculture's plant-inspection agency found sufficient evidence to determine that it was a risk worth taking and considers 2,4-D to be safe. A final decision on the matter will be made by the spring or early summer. And it will consider the views and opinions of what the public has to say about the report.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs